The World Health Organization WHO recently announced its support for the drug Paxlovid.Covid-19 oral form from Pfizer, Inc. in high-risk patients After analyzing WHO clinical trial data on nearly 3,100 patients, the drug might reduce the risk of hospitalization by 85%. xlovid It’s a cure for COVID-19 The most effective compared to the drugs currently available.
However, during the past week Instead, there were reports that some patients had relapsed following 5 days of taking Paxlovid and were more severely ill. The U.S. Food and Drug Administration (FDA) says it does not recommend giving Paxlovidose 2 to patients with relapses. This raises the question of what’s wrong with this drug, despite the fact that in many countries Including Thailand is gradually prescribing this drug to treat patients. Although there are not many cases like this, but they start to experience more symptoms like this. until scientists have to rush to find answers
While Pfizer stated that The company has been reported on this matter. and are seriously investigating The incidence rate for this was similar to the participants who received the counterfeit drug in the clinical trials. Therefore, it should not be confirmed that medication is the direct cause of these symptoms. Like the FDA, regarding 1-2% of the samples studied for the efficacy of Paxlovid showed that their viral levels increased following 10 days. This was similar to the placebo-treated sample. It is unclear whether this is related to Paxlovid treatment.
Meanwhile, experts continue to stress the benefits of the drug. That will definitely help prevent hospitalizations and deaths. In which users must weigh the benefits of the drug and the risks that may occur.re-illor relapse By now, the rate of use of Paxlovid in the United States increased rapidly several times especially during this period when the number of infected people across the United States is on an uptrend once more
Dr Shira Doron, an infectious disease and epidemiologist at Tuft Medical Center, said she saw many patients improving with Paxlovid. But following five days of taking the pills, some people returned with symptoms and tested positive for the virus. And also found the number of viruses that have increased more than ever. This is a matter that researchers are accelerating to answer.
Dr. Michael Charness, chief medical officer at Boston Health Center, is currently researching the phenomenon. stated that in February A case of a 71-year-old patient who has been vaccinated has been found. and recovered from COVID-19 and following receiving Paxlovid but the symptoms relapsed With the number of viruses increasing rapidly within 9 days from the date of first infection. with flu-like symptoms and the infection was detected once more Molecular testing also found that the viral load was higher than when it was first diagnosed, but Dr Charness confirmed that Paxlovid was still a highly effective drug. It only raises doubts as to whether the drug may have a low potential in combating the Omicron-mutant coronavirus. This is because the drug was primarily tested for effectiveness once morest the Delta mutant virus. It is unclear whether this is a new infection. Or is there an adaptation of the infection or how exactly does it mutate? Because such symptoms have been reported in other countries as well.
Representatives of the US Food and Drug Administration, or FDA, said. A team of scientists is investigating the incident. and there will be further instructions. The FDA also emphasized that the report does not alter its conclusions. Paxlovid has reduced hospital admissions and reduced mortality. It shows that the recommendations of the US Centers for Disease Control and Prevention (CDC) are still important. especially those who are sick during quarantine or following detention should remain isolated and still wearing a mask Including checking the infection to make sure that the disease has completely disappeared. For anyone who thinks there is a risk Or close contact with the patient should check for infection to prevent it.
Author : Ajumma Opal
